Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis.
Disease interception
Disease prevention
Early psoriatic arthritis
Psoriasis
Psoriatic arthritis
Systematic review
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
17
08
2021
accepted:
16
09
2021
pubmed:
2
10
2021
medline:
2
10
2021
entrez:
1
10
2021
Statut:
ppublish
Résumé
Agreement on how to identify psoriasis (PsO) patients at risk of developing psoriatic arthritis (PsA) is lacking. To identify predictors, risk factors and incidence rate (IR) of PsA development in PsO patients through a systematic literature review (SLR) and meta-analyses (MA). MEDLINE, Embase, and Cochrane databases were searched. Cohort studies were used to assess the predictors, while case-control studies for PsA risk factor determination. We screened 4698 articles for eligibility, and 110 underwent a full reading and 26 were finally included. Among skin and nail phenotypes, PsO severity and nail pitting were selected as predictors of PsA development. Furthermore, PsO patients with arthralgia (pooled RR 2.15 [1.16; 3.99]) and/or with imaging-MSK inflammation (pooled RR 3.72 [2.12; 6.51]) were at high risk of PsA. Higher categories of BMI and a family history of PsA were other predictors. In outpatient-based cohort studies, the IR of PsA per 100 patient-years varied from 1.34 to 17.4. Despite the strength of the overall results, the heterogeneity and the number of the cohort studies could be considered a limitation. This study provides a tentative profile of the PsO patient at risk of PsA and will help the design of PsA prevention trials.
Sections du résumé
BACKGROUND
BACKGROUND
Agreement on how to identify psoriasis (PsO) patients at risk of developing psoriatic arthritis (PsA) is lacking.
OBJECTIVE
OBJECTIVE
To identify predictors, risk factors and incidence rate (IR) of PsA development in PsO patients through a systematic literature review (SLR) and meta-analyses (MA).
METHODS
METHODS
MEDLINE, Embase, and Cochrane databases were searched. Cohort studies were used to assess the predictors, while case-control studies for PsA risk factor determination.
RESULTS
RESULTS
We screened 4698 articles for eligibility, and 110 underwent a full reading and 26 were finally included. Among skin and nail phenotypes, PsO severity and nail pitting were selected as predictors of PsA development. Furthermore, PsO patients with arthralgia (pooled RR 2.15 [1.16; 3.99]) and/or with imaging-MSK inflammation (pooled RR 3.72 [2.12; 6.51]) were at high risk of PsA. Higher categories of BMI and a family history of PsA were other predictors. In outpatient-based cohort studies, the IR of PsA per 100 patient-years varied from 1.34 to 17.4.
LIMITATIONS
CONCLUSIONS
Despite the strength of the overall results, the heterogeneity and the number of the cohort studies could be considered a limitation.
CONCLUSIONS
CONCLUSIONS
This study provides a tentative profile of the PsO patient at risk of PsA and will help the design of PsA prevention trials.
Identifiants
pubmed: 34596875
doi: 10.1007/s40744-021-00378-w
pii: 10.1007/s40744-021-00378-w
pmc: PMC8572278
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1519-1534Informations de copyright
© 2021. The Author(s).
Références
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–17.
pubmed: 15708927
pmcid: 1766874
Christophers E, Barker JNWN, Griffiths CEM, Daudén E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548–54.
doi: 10.1111/j.1468-3083.2009.03463.x
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–12.
pubmed: 32434812
Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol Nat Publ Group. 2019;15:153–66.
doi: 10.1038/s41584-019-0175-0
Zabotti A, McGonagle DG, Giovannini I, Errichetti E, Zuliani F, Zanetti A, et al. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open. 2019;5:e001067.
doi: 10.1136/rmdopen-2019-001067
Ogdie A. The preclinical phase of PsA: a challenge for the epidemiologist. Ann Rheum Dis. 2017;76:1481–3.
doi: 10.1136/annrheumdis-2017-211109
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
doi: 10.1371/journal.pmed.1000097
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.
doi: 10.1001/jama.283.15.2008
Ottawa Hospital Research Institute [Internet]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed 17 Mar 2021.
Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225–34.
doi: 10.1016/j.jclinepi.2015.06.005
Faustini F, Simon D, Oliveira I, Kleyer A, Haschka J, Englbrecht M, et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheumatic Dis. 2016;75:2068–74 (G. Schett, Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Ulmenweg 18, Erlangen, Germany).
doi: 10.1136/annrheumdis-2015-208821
Elnady B, El Shaarawy NK, Dawoud NM, Elkhouly T, Desouky DE-S, Elshafey EN, et al. Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years. Clin Rheumatol. 2019;38:1627–35 (J.J. Rasker, Department Psychology, Health and Technology, Faculty of Behavioral, Management and Social sciences, University of Twente, PO box 217, Enschede, Netherlands).
doi: 10.1007/s10067-019-04445-0
Eder L, Polachek A, Rosen CF, Chandran V, Cook R, Gladman DD. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol (Hoboken, NJ). 2017;69:622–9.
doi: 10.1002/art.39973
Eder L, Haddad A, Rosen CF, Lee K-A, Chandran V, Cook R, et al. The Incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 2016;68:915–23.
doi: 10.1002/art.39494
Lewinson RT, Vallerand IA, Lowerison MW, Parsons LM, Frolkis AD, Kaplan GG, et al. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study. J Investig Dermatol. 2017;137:828–35 (C. Barnabe, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada).
doi: 10.1016/j.jid.2016.11.032
Egeberg A, Skov L, Zachariae C, Gislason GH, Thyssen JP, Mallbris L, et al. Duration of psoriatic skin disease as risk factor for subsequent onset of psoriatic arthritis. Acta Derm Venereol. 2018;98:546–50.
doi: 10.2340/00015555-2912
Green A, Shaddick G, Charlton R, Snowball J, Nightingale A, Smith C, et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br J Dermatol. 2020;182:714–20.
doi: 10.1111/bjd.18227
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233–9.
doi: 10.1002/art.24172
Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Sokolova M, et al. Structural entheseal lesions in patients with psoriasis are associated with an increased risk of progression to psoriatic arthritis. Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41239 .
doi: 10.1002/art.41239
pubmed: 32103639
Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71:1273–7.
doi: 10.1136/annrheumdis-2012-201299
Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71:1267–72.
doi: 10.1136/annrheumdis-2011-201273
Eder L, Law T, Chandran V, Shanmugarajah S, Shen H, Rosen CF, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63:1091–7.
doi: 10.1002/acr.20496
Eder L, Shanmugarajah S, Thavaneswaran A, Chandran V, Rosen CF, Cook RJ, et al. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2012;71:219–24.
doi: 10.1136/ard.2010.147793
Tsuruta N, Imafuku S, Narisawa Y. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol. 2017;44:1349–52 (S. Imafuku, Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan).
doi: 10.1111/1346-8138.13968
Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71:804–8.
doi: 10.1136/annrheumdis-2011-200416
Nguyen U-SDT, Zhang Y, Lu N, Louie-Gao Q, Niu J, Ogdie A, et al. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann Rheum Dis. 2018;77:119–23.
doi: 10.1136/annrheumdis-2017-211625
Thorarensen SM, Lu N, Ogdie A, Gelfand JM, Choi HK, Love TJ. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2017;76:521–5.
doi: 10.1136/annrheumdis-2016-209334
Thumboo J, Uramoto K, Shbeeb MI, O’Fallon WM, Crowson CS, Gibson LE, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol. 2002;29:757–62.
pubmed: 11950018
Tey HL, Ee HL, Tan ASL, Theng TS, Wong SN, Khoo SW. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol. 2010;37:426–30.
doi: 10.1111/j.1346-8138.2009.00745.x
Muntyanu A, Abji F, Liang K, Pollock RA, Chandran V, Gladman DD. Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. Arthritis Res Ther. 2016;18:296.
doi: 10.1186/s13075-016-1196-6
Abji F, Pollock RA, Liang K, Chandran V, Gladman DD. Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol (Hoboken, NJ). 2016;68:2911–6.
doi: 10.1002/art.39800
Julià A, Tortosa R, Hernanz JM, Cañete JD, Fonseca E, Ferrándiz C, et al. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Hum Mol Genet. 2012;21:4549–57.
doi: 10.1093/hmg/dds295
Eder L, Chandran V, Pellett F, Pollock R, Shanmugarajah S, Rosen CF, et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2011;70:1594–8.
doi: 10.1136/ard.2010.147421
Smolnikova M, Freidin M, Barilo A, Smirnova S. Analysis of association between cytokine gene polymorphisms and psoriatic disease in Russians of East Siberia. Meta Gene. 2018;19:60–4.
doi: 10.1016/j.mgene.2018.10.010
Duffin KC, Freeny IC, Schrodi SJ, Wong B, Feng B-J, Soltani-Arabshahi R, et al. Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol. 2009;129:2777–83.
doi: 10.1038/jid.2009.169
Savage L, Tinazzi I, Zabotti A, Laws PM, Wittmann M, McGonagle D. Defining pre-clinical psoriatic arthritis in an integrated dermato-rheumatology environment. J Clin Med Multidiscip. 2020;9:3262 (Digital Publishing Institute).
doi: 10.3390/jcm9103262
Acosta Felquer ML, LoGiudice L, Galimberti ML, Rosa J, Mazzuoccolo L, Soriano ER. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2021. https://doi.org/10.1136/annrheumdis-2021-220865 .
doi: 10.1136/annrheumdis-2021-220865
pubmed: 34281904
Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2021. https://doi.org/10.1136/annrheumdis-2021-219961 .
doi: 10.1136/annrheumdis-2021-219961
pubmed: 34144965
Ash ZR, Tinazzi I, Gallego CC, Kwok C, Wilson C, Goodfield M, et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. 2012;71:553–6.
doi: 10.1136/annrheumdis-2011-200478
Savage L, Goodfield M, Horton L, Watad A, Hensor E, Emery P, et al. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two–Week, Prospective, Open-Label Feasibility Study. Arthritis Rheumatol (Hoboken, NJ). 2019;71:626–31 (D. McGonagle, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom).
doi: 10.1002/art.40778
Kampylafka E, Simon D, d’Oliveira I, Linz C, Lerchen V, Englbrecht M, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21:178.
doi: 10.1186/s13075-019-1957-0
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.
doi: 10.1002/art.21972
EULAR | ongoing initiatives [Internet]. https://www.eular.org/ongoing_initiatives.cfm . Accessed 14 Sep 2021.